HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm.

This report describes an algorithm for identifying acceptable HLA antigens for highly alloimmunized patients without the need for extensive serum screening. This algorithm is based on the concept that immunogenic epitopes are represented by amino acid triplets on exposed parts of protein sequences of human leukocyte antigen chains (HLA-A, HLA-B, and HLA-C) accessible to alloantibodies. A computer program (HLAMatchmaker) has been developed to determine class I HLA compatibility at the molecular level. It makes intralocus and interlocus comparisons of polymorphic triplets in sequence positions to determine the spectrum of non-shared triplets on donor HLA antigens. In most cases is it possible to identify certain mismatched HLA antigens that share all their polymorphic triplets with the patient's HLA antigens and could therefore, be considered fully compatible. HLAMatchmaker permits also the identification of additional mismatches that are acceptable as determined from the triplet information on HLA-typed panel cells that do not react with patient's serum.HLAMatchmaker provides an assessment of donor-recipient HLA compatibility at the structural level and this algorithm is different from conventional methods based on the mere counting of numbers of mismatched HLA antigens or CREGs. This donor selection strategy is suitable especially for allosensitized patients in need of a compatible transplant or platelet transfusion.

[1]  B. Bradley,et al.  THE PREDICTIVE VALUE OF EPITOPE ANALYSIS IN HIGHLY SENSITIZED PATIENTS AWAITING RENAL TRANSPLANTATION , 1995, Transplantation.

[2]  E. Kabat,et al.  The structural basis of antibody complementarity. , 1978, Advances in protein chemistry.

[3]  I. Doxiadis,et al.  HLAmatchmaker: a molecularly based algorithm for histocompatibility determination. III. Effect of matching at the HLA-A,B amino acid triplet level on kidney transplant survival1 , 2003, Transplantation.

[4]  D. Wiley,et al.  Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. , 1991, Journal of molecular biology.

[5]  P. Parham,et al.  Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA , 1995, The Journal of experimental medicine.

[6]  W. Müller‐ruchholtz,et al.  Serological mapping of HLA-epitopes with monoclonal antibodies and its interpretation by sequenced HLA-molecules. , 1989, Tissue antigens.

[7]  S. Takemoto,et al.  CREG matching for first kidney transplants performed by SEOPF Centers between October 1987 and September 1995: an analysis of outcome and prospective benefit. Southeastern Procurement Foundation. , 1997, Transplantation proceedings.

[8]  B. Dupont,et al.  Immunobiology of HLA , 1989, Springer New York.

[9]  N. Domenech,et al.  Antigenicity of HLA-A2 and HLA-B7. Loss and gain of serologic determinants induced by site-specific mutagenesis at residues 62 to 80. , 1991, Human immunology.

[10]  P. Parham,et al.  A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2 , 1990, Nature.

[11]  P. Parham,et al.  Topographic map of the HLA-A2 CREG epitopes using human alloantibody probes. , 1990, Human immunology.

[12]  P. Colman,et al.  Structure of antibody-antigen complexes: implications for immune recognition. , 1988, Advances in immunology.

[13]  T. Fuller,et al.  HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure. , 1997, Human immunology.

[14]  J. Forejt,et al.  Supertypic HLA-Bw4 antigen detected by a new monoclonal antibody. , 1986, Experimental and clinical immunogenetics.

[15]  Van Regenmortel,et al.  Structure of antigens , 1992 .

[16]  P. Terasaki,et al.  Significance of the HLA molecular structure to transplantation. , 1988, Clinical transplants.

[17]  E. Adams,et al.  The Origins of HLA‐A,B,C Polymorphism , 1995, Immunological reviews.

[18]  W. Vaughn,et al.  THE EFFECT OF HLA‐A, ‐B MATCHING ON CADAVER RENAL ALLOGRAFT REJECTION COMPARING PUBLIC AND PRIVATE SPECIFICITIES , 1984, Transplantation.

[19]  P. Parham,et al.  HLA-B15: a widespread and diverse family of HLA-B alleles. , 1994, Tissue antigens.

[20]  G. Opelz,et al.  Evaluation of the permissible mismatch concept , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[21]  M. V. Regenmortel,et al.  Antigenic cross-reactivity potential of synthetic peptides immobilized on polyethylene rods. , 1991, Molecular immunology.

[22]  J. Scornik,et al.  ENZYME‐LINKED IMMUNOASSAY FOR ANTI‐HLA ANTIBODIES—AN ALTERNATIVE TO PANEL STUDIES BY LYMPHOCYTOTOXICITY , 1993, Transplantation.

[23]  J. Scornik.  HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. , 1987, Human immunology.

[24]  E. Adams,et al.  The HLA-B73 antigen has a most unusual structure that defines a second lineage of HLA-B alleles. , 1994, Tissue antigens.

[25]  J. Thomas,et al.  The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients. , 2002, Human immunology.

[26]  K. Smith,et al.  HLA-B*0702 antibody epitopes are affected indirectly by distant antigen residues. , 1993, Human immunology.

[27]  P. Parham,et al.  Serologic cross-reactivities poorly reflect allelic relationships in the HLA-B12 and HLA-B21 groups. Dominant epitopes of the alpha 2 helix. , 1992, Journal of immunology.

[28]  H. Bilofsky,et al.  Attempts to locate residues in complementarity-determining regions of antibody combining sites that make contact with antigen. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Charpentier,et al.  Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  R. Duquesnoy,et al.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. , 2002, Human immunology.

[31]  F. Delmonico,et al.  New approaches to donor crossmatching and successful transplantation of highly sensitized patients. , 1983, Transplantation.

[32]  P. Parham,et al.  Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8. , 1989, Nature.

[33]  J. McCutcheon,et al.  Mutagenesis around residue 176 on HLA-B*0702 characterizes multiple distinct epitopes for anti-HLA antibodies. , 1992, Human immunology.

[34]  P. Parham,et al.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C , 1992, The Journal of experimental medicine.

[35]  R. Bray,et al.  Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. , 1994, Human immunology.

[36]  P. Parham,et al.  Polymorphism in the α3 domain of HLA-A molecules affects binding to CD8 , 1989, Nature.

[37]  D. Wiley,et al.  Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[38]  I. Doxiadis,et al.  Acceptable HLA mismatches for highly immunized patients. , 1999, Reviews in immunogenetics.

[39]  I. Doxiadis,et al.  Cross-reactive group matching does not lead to a better allocation and survival of donor kidneys. , 2000, Transplantation.

[40]  H. Sollinger,et al.  Adsorption of cytotoxic anti-HLA antibodies with HLA class I immunosorbant beads. , 1990, Transplantation.

[41]  Dean R. Madden,et al.  The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC , 1992, Cell.

[42]  P. Parham,et al.  HLA-Bw22: a family of molecules with identity to HLA-B7 in the alpha 1-helix. , 1992, Journal of immunology.

[43]  T. Potter,et al.  Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S J Rodda,et al.  A priori delineation of a peptide which mimics a discontinuous antigenic determinant. , 1986, Molecular immunology.

[45]  T. Fuller,et al.  Public epitopes and the antigenic structure of the HLA molecules. , 1987, Critical reviews in immunology.

[46]  J. Scornik.  Detection of alloantibodies by flow cytometry: relevance to clinical transplantation. , 1995, Cytometry.

[47]  R. Rossen,et al.  Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. , 2008, Tissue antigens.

[48]  B. Susskind,et al.  Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. , 1996, Transplantation.

[49]  R. W. Vaughn,et al.  Detection of HLA class I- and class II-specific antibodies by flow cytometry and PRA-STAT screening in renal transplant recipients. , 1997, Transplantation.

[50]  A. Zachary,et al.  Evaluation of HLA antibodies with the PRA-STAT test. An ELISA test using soluble HLA class I molecules. , 1995, Transplantation.

[51]  L. Brown,et al.  Epitopes of an influenza viral peptide recognized by antibody at single amino acid resolution. , 1988, Journal of immunology.

[52]  S. Takemoto,et al.  Benefits of HLA-CREG matching for sensitized recipients as illustrated in kidney regrafts. , 1997, Transplantation proceedings.

[53]  K. Smith,et al.  Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. , 1994, Journal of immunology.

[54]  S. Takemoto,et al.  Anti-HLA antibodies after solid organ transplantation. , 2000, Transplantation.

[55]  H. V. van Houwelingen,et al.  Taboo HLA mismatches in cadaveric renal transplantation: definition, analysis, and possible implications. , 1996, Transplantation proceedings.

[56]  R. Karr,et al.  HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes. , 1994, Human immunology.

[57]  P. Nickerson,et al.  Matching for private or public HLA epitopes reduces acute rejection episodes and improves two-year renal allograft function. , 1998, Transplantation.

[58]  J. Vorlíček,et al.  Quantitative estimation of HLA-A and HLA-B antigens carrying the Bw4 supertypic specificity in human peripheral blood lymphocytes , 2004, Immunogenetics.

[59]  P. A. Biro,et al.  Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. , 1988, Journal of immunology.

[60]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[61]  A. Zachary,et al.  VARIATIONS OF THE LYMPHOCYTOTOXICITY TEST AN EVALUATION OF SENSITIVITY AND SPECIFICITY , 1995, Transplantation.

[62]  D. Phelan,et al.  ANTIGENIC SPECIFICITY OF ANTIBODY REACTIVE IN THE ANTIGLOBULIN‐AUGMENTED LYMPHOCYTOTOXICITY TEST , 1982, Transplantation.

[63]  T. Starzl,et al.  HLA and cross-reactive antigen group matching for cadaver kidney allocation. , 1997, Transplantation.

[64]  F. Claas,et al.  Hyperimmunized patients do not need to wait for an HLA identical donor. , 1989, Tissue antigens.

[65]  R. Duquesnoy,et al.  Determination of HLA-A,B residue mismatch acceptability for kidneys transplanted into highly sensitized patients: a report of a collaborative study conducted during the 12th International Histocompatibility Workshop. , 1997, Transplantation.

[66]  F. Claas,et al.  Transplantation of highly sensitized patients on the basis of acceptable HLA-A and B mismatches. , 1989, Clinical transplants.

[67]  R. Tosi,et al.  Low immunogenicity of the third HL-A series. , 1975, Transplantation.

[68]  D. Phelan,et al.  Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies. , 1986, Transplantation.

[69]  G. Air,et al.  Epitopes on protein antigens: Misconceptions and realities , 1990, Cell.

[70]  P. Parham,et al.  Epitope map of the HLA-B7 CREG using affinity-purified human alloantibody probes. , 1990, Human immunology.

[71]  R. Lerner,et al.  The chemistry and mechanism of antibody binding to protein antigens. , 1988, Advances in immunology.

[72]  Janet W. Fierst,et al.  MULTISCREEN SERUM ANALYSIS OF HIGHLY SENSITIZED RENAL DIALYSIS PATIENTS FOR ANTIBODIES TOWARD PUBLIC AND PRIVATE CLASS I HLA DETERMINANTS: IMPLICATIONS FOR COMPUTER‐PREDICTED ACCEPTABLE AND UNACCEPTABLE DONOR MISMATCHES IN KIDNEY TRANSPLANTATION , 1990, Transplantation.

[73]  H Grosse-Wilde,et al.  Detection of panel-reactive anti-HLA class I antibodies by enzyme-linked immunosorbent assay or lymphocytotoxicity. Results of a blinded, controlled multicenter study. , 1995, Human immunology.

[74]  P. Tomasulo,et al.  Role of HLA-C matching in histocompatible platelet transfusion therapy of alloimmunized thrombocytopenic patients. , 1977, Transplantation proceedings.

[75]  M. Petzl-Erler,et al.  Structural diversity in the HLA-A10 family of alleles: correlations with serology. , 1993, Tissue antigens.

[76]  P. Parham,et al.  HLA-B67: a member of the HLA-B16 family that expresses the ME1 epitope. , 1994, Tissue antigens.

[77]  J. Thompson,et al.  CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995. Southeastern Organ Procurement Foundation. , 1996, Clinical transplantation.

[78]  Thompson Js,et al.  CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995. Southeastern Organ Procurement Foundation. , 1996 .

[79]  T. Fuller,et al.  Epitope specificity of HLA class I alloantibodies: II. Stability of cross-reactive group antibody patterns over extended time periods. , 1997, Transplantation.